Data Insights

Sefaxersen sodium by F. Hoffmann-La Roche for Geographic Atrophy: Likelihood of Approval

Sefaxersen sodium is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Geographic Atrophy. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Sefaxersen Sodium in Geographic Atrophy

Data Insights

Entrectinib by F. Hoffmann-La Roche for Metastatic Pancreatic Cancer: Likelihood of Approval

Entrectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Metastatic Pancreatic Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Entrectinib in Metastatic Pancreatic Cancer

Data Insights

Idasanutlin by F. Hoffmann-La Roche for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

Idasanutlin is under clinical development by F. Hoffmann-La Roche and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Idasanutlin in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

Satralizumab by F. Hoffmann-La Roche for Myasthenia Gravis: Likelihood of Approval

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Myasthenia Gravis. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Myasthenia Gravis

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Thymic Carcinoma: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Thymic Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Thymic Carcinoma

Data Insights

Alectinib by F. Hoffmann-La Roche for Inflammatory Myofibroblastic Tumor (IMT): Likelihood of Approval

Alectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Inflammatory Myofibroblastic Tumor (IMT). According...

Likelihood of Approval and Phase Transition Success Rate Model - Alectinib in Inflammatory Myofibroblastic Tumor (IMT)

Data Insights

Alectinib by F. Hoffmann-La Roche for Central Nervous System (CNS) Tumor: Likelihood of Approval

Alectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Central Nervous System (CNS) Tumor....

Likelihood of Approval and Phase Transition Success Rate Model - Alectinib in Central Nervous System (CNS) Tumor

Data Insights

Alectinib by F. Hoffmann-La Roche for High-Grade Glioma: Likelihood of Approval

Alectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for High-Grade Glioma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Alectinib in High-Grade Glioma

Data Insights

Alectinib by F. Hoffmann-La Roche for Renal Cell Carcinoma: Likelihood of Approval

Alectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Renal Cell Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Alectinib in Renal Cell Carcinoma

Data Insights

Tocilizumab by F. Hoffmann-La Roche for Non-Small Cell Lung Cancer: Likelihood of Approval

Tocilizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Tocilizumab in Non-Small Cell Lung Cancer

Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Peritoneal Cancer: Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Peritoneal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Peritoneal Cancer

Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Human Epidermal Growth Factor...

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Metastatic Breast Cancer: Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Metastatic Breast Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Metastatic Breast Cancer

Data Insights

Cobimetinib fumarate by F. Hoffmann-La Roche for Fallopian Tube Cancer: Likelihood of Approval

Cobimetinib fumarate is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Fallopian Tube Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Fallopian Tube Cancer

Data Insights

Atezolizumab by F. Hoffmann-La Roche for Anal Cancer: Likelihood of Approval

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Anal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Anal Cancer

Data Insights

Astegolimab by F. Hoffmann-La Roche for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval

Astegolimab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Chronic Obstructive Pulmonary Disease (COPD)....

Likelihood of Approval and Phase Transition Success Rate Model - Astegolimab in Chronic Obstructive Pulmonary Disease (COPD)

Data Insights

Satralizumab by F. Hoffmann-La Roche for Demyelinating Diseases: Likelihood of Approval

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Demyelinating Diseases. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Demyelinating Diseases

Data Insights

Alectinib by F. Hoffmann-La Roche for Solid Tumor: Likelihood of Approval

Alectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Solid Tumor. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Alectinib in Solid Tumor

Data Insights

Obinutuzumab by F. Hoffmann-La Roche for Nephrotic Syndrome: Likelihood of Approval

Obinutuzumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Nephrotic Syndrome. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Obinutuzumab in Nephrotic Syndrome

Data Insights

Rituximab by F. Hoffmann-La Roche for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Rituximab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Marginal Zone B-cell Lymphoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Marginal Zone B-cell Lymphoma